Erratum: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis (PLoS ONE (2018) 13:8 (e0203058) DOI: 10.1371/journal.pone.0203058)

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The following information is missing from the Competing Interests statement: Dr. Harald Matthes is a member of the board of directors at Weleda AG, a company that until 2016 distributed Iscador, a mistletoe preparation. In addition, Dr. Harald Matthes is a member of the board of the Hufelandgesellschaft e. V. in Germany; President of the DAHN (German Academy for Homeopathy and Naturopathy); and medical director and managing director of Gemeinschaftskrankenhaus Havelhöhe, a hospital for anthroposophic medicine. Dr. Harald Matthes is also a recipient on an endowed professorship from Charité in Berlin on Integrative and Anthroposophical Medicine. These competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Cite

CITATION STYLE

APA

Schad, F., Thronicke, A., Steele, M. L., Merkle, A., Matthes, B., Grah, C., & Matthes, H. (2022, August 1). Erratum: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis (PLoS ONE (2018) 13:8 (e0203058) DOI: 10.1371/journal.pone.0203058). PLoS ONE. Public Library of Science. https://doi.org/10.1371/journal.pone.0273387

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free